Mobile health app to improve quality of life for Black prostate cancer survivors
Official title: Development and Preliminary Evaluation of a Tailored mHealth App Designed to Improve Quality-of-Life Outcomes in Ethnically-Diverse Black Prostate Cancer Survivors (SAFE-CaPs)
Run by University of Oklahoma · NCT06651359 · Data updated 2026-11-12
This study is testing a mobile health app designed for Black men with prostate cancer to see if it can help improve their quality of life during and after treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 248 (estimated) |
| Sponsor | University of Oklahoma Academic / other |
| Locations | 3 sites (Tallahassee, Florida and 2 other locations) |
| Status | Recruiting |
| Started | August 24, 2025 |
| Main results expected | October 2029 |
| Study ends | November 2030 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT06651359 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are ethnically diverse Black men who are within the first five years of their prostate cancer survivorship journey.
✕Probably not a fit
Patients who are not Black, have never been diagnosed with prostate cancer, or do not own a smartphone will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate a mobile health application designed specifically for ethnically diverse Black men with prostate cancer, whether they are currently undergoing treatment or are survivors. The app will provide tailored information, symptom monitoring, and patient testimonials to empower users in their care. Participants will complete online surveys at the start and at 3, 6, 9, and 12 months, with a subset using the app for daily symptom tracking and weekly mood assessments. Feedback will be gathered through interviews at the end of the study to enhance the app's effectiveness.
Why it matters
Potential benefit: If successful, this app could significantly improve the quality of life and engagement in care for Black prostate cancer survivors.
How similar studies have gone: While mobile health interventions have shown promise in various populations, this specific culturally tailored approach for Black prostate cancer survivors is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Ethnically-diverse Black prostate cancer (CaP) survivors who are either native-born, Caribbean-born, or African-born Exclusion Criteria: * Men from other races. * Men who have never been diagnosed with CaP * Men who have the inability to speak English
Where it's running
-
Florida State University
Tallahassee, Florida, United States Recruiting -
Georgia College & State University
Milledgeville, Georgia, United States Recruiting -
University of Oklahoma HSC
Oklahoma City, Oklahoma, United States Recruiting
Study contacts
- Principal investigator: Motolani Adedipe, PhD, DPh, MS — University of Oklahoma
- Study coordinator: Motolani Adedipe, PhD, DPh, MS
- Email: Motolani-adedipe@ouhsc.edu
- Phone: (405)-271-8001
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.